Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering

Journal of Clinical Lipidology

Volumn 6, Issue 4, 2012, Pages 303-309

  Sniderman, Allan ^a   Thanassoulis, George ^a   Couture, Patrick ^b   Williams, Ken ^c   Alam, Ahsan ^a   Furberg, Curt D ^d  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Guidelines; Low density lipoprotein cholesterol; Prevention; Therapy

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

BRAIN ISCHEMIA; HEART INFARCTION; HUMAN; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 84864289007     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2012.05.004     Document Type: Editorial

References (34)

1. S.M. Grundy, J.I. Cleeman, and C.N. Merz National Heart Lung and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
2. A.L. Catapano, Z. Reiner, and G. De Backer ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 Suppl 1 2011 1 44
3. Cholesterol Treatment Trialists' CTT Collaborators Efficacy and safely of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomized trials of statins Lancet 205 2005 1267 1278
4. J.C. LaRosa, S.M. Grundy, and D.D. Waters Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
5. C.P. Cannon, E. Braunwald, and C.H. McCabe Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
6. T.R. Pedersen, O. Faergeman, J.J.P. Kastelein Incremental Decrease in End points through Aggressive Lipid Lowering (IDEAL) study group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction J Am Med Assoc 294 2005 2437 2445 (Pubitemid 41627921)
7. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomized trial Lancet 376 2010 1658 1669
8. J.A. de Lemos, M.A. Blazing, S.D. Wiviott A to Z Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndrome. Phase Z of the A to Z Trial J Am Med Assoc 292 2004 1307 1316 (Pubitemid 39223221)
9. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials Lancet 376 2010 1670 1681
10. R.A. Hayward, and H. Krumholz Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health Circ Cardiovasc Qual Outcomes 5 2012 2 5
11. The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts N Engl J Med 336 1997 153 162
12. V.G. Athros, D.P. Mikhailidis, and A.A. Papageorgiou Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study Curr Med Res Opin 20 2004 1385 1392 (Pubitemid 39361342)
13. J.G. Robinson, B. Smith, N. Maheshwari, and H. Schrott Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis J Am Coll Cardiol 46 10 2005 1855 1862 (Pubitemid 41579807)
14. National Centre for Health Statistics Center for Disease Control and Prevention. The National Health and Nutrition Examination Survey (NHANES) Analytic Guidelines. Available at: http://www.cdc.gov/nchs/nhanes/nhanes2003- 2004/analytical-guidelines.htm. Accessed May 7, 2012.
15. Cholesterol Treatment Trialists' (CTT) Collaboration Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens Am J Cardiol 75 1995 1130 1134
16. S. Mora, N.K. Wenger, and D.A. Demicco Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study Circulation 125 2012 1979 1987
17. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
18. S.M. Grundy, J.I. Cleeman, and C.N. Merz National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
19. S.M. Boekholdt, B.J. Arsenault, and S. Mora Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
20. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sawar, and P. Perry Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
21. A.D. Sniderman, K. Williams, and J.H. Contois A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
22. S. Mora, R.J. Glynn, S.M. Boekholdt, B.G. Nordestgaard, J.J. Kastelein, and P.M. Ridker On-treatment non-high-density lipoprotein cholesterol, apolipoprotein b, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol 59 2012 1521 1528
23. T.R. Joy, and R.A. Hegele Narrative review: statin-related myopathy Ann Intern Med 150 2009 858 868
24. G.B. Mancini, S. Baker, and D. Bergeron Diagnosis, Prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 2011 635 662
25. J.N. Rasmussen, A. Chong, and D.A. Alter Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction J Am Med Assoc 297 2007 177 186 (Pubitemid 46089734)
26. R.J.J. Simpson, and P. Mendys The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review J Clin Lipidol 4 2010 462 471
27. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
28. A.D. Sniderman Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidol 2 2008 36 42 (Pubitemid 351250867)
29. A.D. Sniderman, K. Williams, M.J. McQueen, and C.D. Furberg When is equal not equal? J Clin Lipidol 4 2010 83 88
30. H.M. Colhoun, D.J. Betteridge, P.N. Durrington CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696 (Pubitemid 39140624)
31. P. Amarenco, J. Bogousslavsky, A. Callahan 3rd Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559 (Pubitemid 44202151)
32. P.M. Ridker, E. Danielson, F.A. Fonseca JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
33. C.P. Cannon, R.P. Giugliano, and M.A. Blazing IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial: Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome Am Heart J 156 2008 826 832
34. L.J. Cohen An Introduction to the Philosophy of Induction and Probability 1989 Oxford University Press New York